News
T-DXd followed by THP improved pCR in high-risk, early-stage HER2+ breast cancer in the phase 3 DESTINY-Breast11 trial.
Researchers sought to determine whether combination venetoclax and pegcrisantaspase would be effective in patients with AML.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback